We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYBR
201
DELISTED
CyberArk
CYBR
$331K ﹤0.01%
2,100
– –
MKC icon
202
McCormick & Company Non-Voting
MKC
$13.4B
$324K ﹤0.01%
4,000
– –
EA icon
203
Electronic Arts
EA
$52.4B
$323K ﹤0.01%
2,270
– –
ST icon
204
Sensata Technologies
ST
$6.65B
$323K ﹤0.01%
5,900
– –
DLB icon
205
Dolby
DLB
$4.72B
$317K ﹤0.01%
3,600
– –
GGG icon
206
Graco
GGG
$12.9B
$315K ﹤0.01%
4,500
– –
BF.B icon
207
Brown-Forman Class B
BF.B
$12B
$308K ﹤0.01%
4,600
– –
TCOM icon
208
Trip.com Group
TCOM
$27.5B
$308K ﹤0.01%
10,000
– –
STZ icon
209
Constellation Brands
STZ
$22.2B
$307K ﹤0.01%
1,459
– –
ANSS
210
DELISTED
Ansys
ANSS
$306K ﹤0.01%
900
– –
CSGP icon
211
CoStar Group
CSGP
$11.3B
$301K ﹤0.01%
3,500
– –
AZPN
212
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$295K ﹤0.01%
2,400
– –
MELI icon
213
Mercado Libre
MELI
$91.3B
$285K ﹤0.01%
170
– –
MKTX icon
214
MarketAxess Holdings
MKTX
$4.15B
$278K ﹤0.01%
662
– –
JD icon
215
JD.com
JD
$40.8B
$260K ﹤0.01%
3,600
– –
SPOT icon
216
Spotify
SPOT
$99.2B
$248K ﹤0.01%
1,100
– –
OLED icon
217
Universal Display
OLED
$3.71B
$233K ﹤0.01%
1,365
– –
IPGP icon
218
IPG Photonics
IPGP
$3.89B
$214K ﹤0.01%
1,350
– –
STNE icon
219
StoneCo
STNE
$2.62B
$149K ﹤0.01%
4,300
– –
CVAC
220
CALL
DELISTED
CureVac
CVAC
$1K ﹤0.01%
120
+50
+71% +$3.01K
ACAD icon
221
Acadia Pharmaceuticals
ACAD
$4.25B
– –
-65,900
Closed -$1.61M
RXRX icon
222
Recursion Pharmaceuticals
RXRX
$1.57B
– –
-20,000
Closed -$730K
SGFY
223
DELISTED
Signify Health, Inc.
SGFY
– –
-200,000
Closed -$6.09M
EAR
224
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-21,703
Closed -$17.3M
XENT
225
DELISTED
Intersect ENT, Inc
XENT
– –
-617,968
Closed -$10.6M
6 7 8
9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.